Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | PHASE1 | COMPLETED | 128 | — | — | Apr 14, 2015 | Jul 5, 2019 | Nov 29, 2019 | 10 | United States |
Maximum tolerated dose is defined as the highest dose level at which less than 2 of 6 participants experience the same dose limiting toxicity. If more than 2 participants experience a different dose limiting toxicity, the maximum tolerated dose may be further evaluated or determined to be exceeded based on discussions with the investigators and medical monitors.
Area under the plasma concentration versus time curve from time 0 (pre-dose) to the time of the last measurable concentration (AUC 0-t).
| Arm | Type | Description |
|---|---|---|
| ABBV-075 | EXPERIMENTAL | Dose escalation cohorts of ABBV-075 monotherapy |
| ABBV-075 and venetoclax combination | EXPERIMENTAL | Expansion cohorts of ABBV-075 and venetoclax combination therapy |
| ABBV-075 expansion | EXPERIMENTAL | Expansion cohorts of ABBV-075 monotherapy |
| Name | Type | Description |
|---|---|---|
| ABBV-075 | DRUG | ABBV-075 Oral tablets |
| Venetoclax | DRUG | Venetoclax tablets, film-coated |
Inclusion Criteria: 1. Participant in the dose escalation cohorts must have histological confirmation of locally advanced or metastatic solid tumor that is either refractory after standard of care therapy for the disease or for which standard of care therapy or does not exist. 2. Participants in th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |